Brief: Xpro™ Reduces Amyloid And Enhances Behavior Post
10/06/2025 21:10
June 10 (Reuters) - INmune Bio Inc INMB.O: XPRO™ REDUCES AMYLOID AND ENHANCES BEHAVIOR POST TRAUMATIC BRAIN INJURY IN AN ANIMAL MODEL OF ALZHEIMER’S DISEASE: SUPPORTED BY DEPARTMENT OF DEFENSE Source text: ID:nGNE2JZF0p Further company coverage: INMB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview